<div id="readability-page-1"><div> WeInfuse expands its revenue cycle capabilities and practice management system by integrating with VETRIQ to automate the last mile of the revenue cycle., /PRNewswire/ -- WeInfuse, the premier software and technology platform for infusion providers and specialty pharmacies, has announced a strategic partnership with VETRIQ, a leading revenue cycle management (RCM) intelligence engine. Together, the two companies are simplifying the complexity of RCM through a seamless, data-driven integration. <img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2931681/WeInfuse_partners_VETRIQ.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="400" height="400" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2931681/WeInfuse_partners_VETRIQ.jpg"/> Infusion teams consistently spend too much money and time on manual processes related to RCM, including everything that hits the bank lockbox. Revenue cycle processes such as deposit reconciliation, posting physical insurer and patient payment checks, posting explanation of benefits (EOBs) with no electronic remittance advice (ERA), and volumes of insurer mail correspondence are handled manually by RCM teams. Mistakes are inherent with these manual processes delaying the timing and accuracy of financial reporting.WeInfuse has integrated with VETRIQ to automate these revenue cycle processes. VETRIQ's technology, including its native artificial intelligence (AI) engine, reconciles bank deposits, converts EOBs and paper checks to 835 files for auto-posting, and reads and organizes payer correspondence. With VETRIQ, infusion providers focus on collections and exception management, not mundane manual tasks.&#34;As a former infusion center operator who has lived and breathed RCM, I am thrilled we have the opportunity to partner with WeInfuse to deliver a seamless, automated solution that streamlines the last mile of the infusion revenue cycle,&#34; said VETRIQ CEO Aaron Smith. &#34;By bringing VETRIQ's AI-driven automation together with WeInfuse's operational excellence, we're empowering RCM teams to eliminate manual bottlenecks, accelerate cash flow, and focus on real RCM issues that require manual intervention like appeals and payer negotiations. This integration marks a major step forward in helping infusion providers unlock efficiency in the revenue cycle.&#34;Mutual VETRIQ and WeInfuse clients will gain automation without having to migrate systems or change lockbox providers. With the VETRIQ integration, WeInfuse clients can go live in weeks, not months.&#34;By partnering with VETRIQ, we are stripping away the manual processes so billing teams can focus on denials and following up on unpaid claims,&#34; said WeInfuse CEO Bryan Johnson. &#34;This integration eliminates the delays and costly errors that regularly plague the revenue cycle by digitizing many steps in the process, giving teams back financial control and valuable time.&#34;About VETRIQVETRIQ is an automation-first healthcare technology company that eliminates manual friction across healthcare revenue reconciliation workflows. By connecting remittance data, payer correspondence, and bank deposits into a unified reconciliation workflow, VETRIQ automates high-volume, error-prone processes such as EOB-to-835 conversion, correspondence indexing, and bank-to-remit matching—reducing manual labor, accelerating cash posting, and delivering operational clarity across financial handoffs. Learn more at vetriq.com.About WeInfuseWeInfuse is the premier technology and consulting provider for infusion therapy and medication delivery in the U.S. The WeInfuse software platform powers the end-to-end workflow for infusion centers and home infusion and specialty pharmacies nationwide. WeInfuse's modern, purpose-built workflows for all sites of care allow pharmacies and providers to improve patient care and scale operations with confidence. Take the confusion out of infusion and learn more at weinfuse.com. <img width="12" height="12" src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wMy0xMSZzbj1EQTA3OTQ1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wMy0xMSZzbj1EQTA3OTQ1"/> View original content to download multimedia:https://www.prnewswire.com/news-releases/weinfuse-and-vetriq-launch-integration-to-automate-the-final-mile-of-the-infusion-revenue-cycle-302711259.htmlSOURCE WeInfuse</div></div>

IBBQ

标普生物技术 3 倍做多 - Direxion

VTRO

WeInfuse 已与 VETRIQ 合作，通过自动化输液收入周期的最后一公里来增强其收入周期管理。此集成旨在减少手动流程，提高效率，并加速输液提供商的现金流。VETRIQ 的人工智能技术将简化存款对账和支付处理等任务，使收入周期管理团队能够专注于更关键的问题。客户可以快速实施此集成，而无需更改系统，从而最终改善财务控制并减少收入周期中的错误

WeInfuse and VETRIQ Launch Integration to Automate the Final Mile of the Infusion Revenue Cycle

fidelity

Invesco Nasdaq Biotechnology ETF

Vitro Biopharma

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

InfuSystems控股

纳斯达克生物科技指数 ETF - iShares Nasdaq

WeInfuse 和 VETRIQ 推出集成解决方案，以自动化输液收入周期的最后阶段